82 related articles for article (PubMed ID: 22396958)
1. [Could the VAD protocol be the first line therapy for multiple myeloma in subSaharan Africa? The Brazzaville experience].
Dokekias AE
Sante; 2011; 21(3):169-70. PubMed ID: 22396958
[No Abstract] [Full Text] [Related]
2. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
[No Abstract] [Full Text] [Related]
3. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
Ross DM; To LB; Horvath N
Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273
[TBL] [Abstract][Full Text] [Related]
4. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
5. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
6. High dose dexamethasone as first line therapy of multiple myeloma? A case report.
Meregalli M; Bertola G; Grando D
Recenti Prog Med; 1998 Jan; 89(1):18-20. PubMed ID: 9549388
[TBL] [Abstract][Full Text] [Related]
7. [Comparative evaluation of treatment results in advanced multiple myeloma with the help of polychemotherapy with vincristine, doxorubicin, dexamethasone (VAD) or only with dexamethasone].
Hansz J; Włodarczyk M; Psuja P
Acta Haematol Pol; 1992; 23(4):277-84. PubMed ID: 1293910
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
9. The treatment of multiple myeloma.
Alexanian R; Dimopoulos M
N Engl J Med; 1994 Feb; 330(7):484-9. PubMed ID: 8289856
[No Abstract] [Full Text] [Related]
10. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
11. [VAD regimen for multiple myeloma--the effectiveness as first line therapy].
Fujii Y; Nisimura Y; Tanizawa Y; Azuno Y; Yaga K; Hirosige Y; Kaku K; Kaneko T; Matumoto N
Rinsho Ketsueki; 1991 Mar; 32(3):280-2. PubMed ID: 2041172
[TBL] [Abstract][Full Text] [Related]
12. Bilateral transient hearing loss associated with vincristine therapy: case report.
Aydogdu I; Ozturan O; Kuku I; Kaya E; Sevinc A; Yildiz R
J Chemother; 2000 Dec; 12(6):530-2. PubMed ID: 11154039
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
Maniatis A; Stamatellou M; Papanastasiou K
Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
[No Abstract] [Full Text] [Related]
14. Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?
Dimopoulos MA; Kastritis E
Leuk Lymphoma; 2006 Nov; 47(11):2271-2. PubMed ID: 17107895
[No Abstract] [Full Text] [Related]
15. Combination chemotherapy of ranimustine, doxorubicine, and dexamethasone for relapsing multiple myeloma--a pilot study.
Murakami H; Yamane A; Sawamura M; Matsumoto M; Murayaman K; Shimano S; Jinbo T; Yokohama A; Uchiumi H; Handa H; Matsushima T; Tsukamoto N; Morita K; Karasawa M; Ogawara H; Nojima Y
J Med; 2003; 34(1-6):39-46. PubMed ID: 17682310
[TBL] [Abstract][Full Text] [Related]
16. HyperCVAD for VAD-resistant multiple myeloma.
Dimopoulos MA; Weber D; Kantarjian H; Delasalle KB; Alexanian R
Am J Hematol; 1996 Jun; 52(2):77-81. PubMed ID: 8638645
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G
Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062
[No Abstract] [Full Text] [Related]
18. Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma.
Young RI; Ranson M; Chang J; Lord B; Testa N; Scarffe JH
Eur J Cancer; 1997 Feb; 33(2):307-11. PubMed ID: 9135507
[TBL] [Abstract][Full Text] [Related]
19. VAD-based regimens as primary treatment for multiple myeloma.
Alexanian R; Barlogie B; Tucker S
Am J Hematol; 1990 Feb; 33(2):86-9. PubMed ID: 2301376
[TBL] [Abstract][Full Text] [Related]
20. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
Barlogie B; Smith L; Alexanian R
N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]